Cargando…
Drug repurposing in autosomal dominant polycystic kidney disease: back to the future with pioglitazone
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited cause of end-stage kidney failure. At present, only one drug, tolvaptan, has been approved for use to slow disease progression, but its use is limited by reduced tolerability and idiosyncratic liver toxicity. Thiazolid...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243263/ https://www.ncbi.nlm.nih.gov/pubmed/34221378 http://dx.doi.org/10.1093/ckj/sfab062 |